Mumbai, Feb. 2 -- TB Alliance is a non-profit drug developer.

Under the terms of the agreement, Lupin and TB Alliance will collaborate to support the clinical development and commercialization of Telacebec, to provide advanced treatment options for patients affected by these diseases. TB Alliance will continue to lead the development process, while Lupin will provide its expertise in global manufacturing, regulatory affairs, and supply chain to ensure global access to Telacebec.

Ramesh Swaminathan, executive director, Global CFO, and Head of IT and API Plus SBU, Lupin, said, "This collaboration with TB Alliance underscores Lupin's enduring commitment to improving patient outcomes in areas of significant unmet medical need. By leveraging...